Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: Individual participant data analysis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 9, 2017, Pages

  Franklin, Jeremy ^a   Eichenauer, Dennis A ^a   Becker, Ingrid ^a   Monsef, Ina ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ACUTE LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADJUVANT RADIOTHERAPY; BASAL CELL CARCINOMA; BILE DUCT CANCER; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CHEMORADIOTHERAPY; COLON CANCER; DRUG DOSE INTENSIFICATION; ESOPHAGUS CANCER; EXTENDED FIELD RADIOTHERAPY; GALLBLADDER CANCER; HODGKIN DISEASE; HUMAN; INVOLVED FIELD RADIOTHERAPY; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASM; MELANOMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NERVOUS SYSTEM CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; SECOND MALIGNANT NEOPLASM; SECONDARY ACUTE LEUKEMIA; SECONDARY MALIGNANT NEOPLASM FREE SURVIVAL; SIGMOID CANCER; SOFT TISSUE CANCER; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SURVIVAL; SYSTEMATIC REVIEW; THYROID CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; ADULT; DISEASE FREE SURVIVAL; LEUKEMIA; MIDDLE AGED; MORTALITY; PROCEDURES; RADIOTHERAPY DOSAGE; SECOND CANCER; STANDARDS;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HODGKIN DISEASE; HUMANS; LEUKEMIA, RADIATION-INDUCED; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VINBLASTINE;

EID: 85029370711     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008814.pub2     Document Type: Review

References (108)

1. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. Journal of Clinical Oncology 2002;20(18):3765-71. 6678169
2. Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherpay for children with Hodgkin's lymphoma - a report from the Children's Oncology Group. Journal of Clinical Oncology 2012;30(26):3174-80. 6678170
3. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology 2013;31(6):684-91. 6678172
4. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. New England Journal of Medicine 2003;348(24):2396-406. 6678174
5. Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New England Journal of Medicine 2007;357(19):1916-27. 6678176
6. Thomas J, Ferme C, Noordijk EM, van't Veer MB, Brice P, Divine M, et al. Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). Haematologica 2007;92(Suppl. 5):27. 6678178
7. Thomas J, Ferme C, Noordijk EM, van't Veer MB, Brice P, Divine M, et al. Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). Haematologica 2007;92(Suppl. 5):27. 6678180
8. Gerhartz HH, Schwenke H, Bazarbashi S, Thiel E, Blau W, Huhn D, et al. Randomized comparison of COPP/ABVD versus dose- and time-escalated COPP/ABVD with GM-CSF support for advanced Hodgkin's disease. ASCO Annual Meeting Proceedings. 1997. 6678182
9. Gerhartz HH, Schwenke H, Bazarbashi S, Thiel E, Blau W, Huhn D, et al. Randomized comparison of COPP/ABVD versus dose- and time-escalated COPP/ABVD with GM-CSF support for advanced Hodgkin's disease. Oncology. 1999; Vol. 13:31. 6678183
10. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. New England Journal of Medicine 2010;363(7):640-52. 6678185
11. Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of Clinical Oncology 2010;28(27):4199-206. 6678187
12. Diehl V, Loeffler M, Pfreundschuh M, Ruehl U, Hasenclever D, Nisters-Backes H, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. Annals of Oncology 1995;6(9):901-10. 6678189
13. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 2003;21(19):3601-8. 6678191
14. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine 2003;348(24):2386-95. 6678193
15. Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi trial. Journal of Clinical Oncology 2009;27(5):805-11. 6678195
16. Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. Journal of Clinical Oncology 2011;29(32):4227-33. 6678197
17. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. New England Journal of Medicine 2011;365(3):203-12. 6678199
18. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. Journal of Clinical Oncology 2004;22(14):2835-41. 6678201
19. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, et al. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children's Oncology Group. Journal of Pediatric Hematology/Oncology 2006;28:362-8. 6678203
20. Anselmo AP, Cavalieri E, Osti FM, Cantonetti M, De Sanctis V, Alfo M, et al. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy. Anticancer Research 2004;24(6):4045-50. 6678205
21. Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. Journal of Clinical Oncology 2004;22(1):62-8. 6678207
22. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519). Journal of Clinical Oncology 2005;23(36):9208-18. 6678209
23. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519). Journal of Clinical Oncology 2005;23(36):9208-18. 6678211
24. Hoskin PJ, Lowry L, Horwich A, Jack A, Mead B, Hancock BW, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group study ISRCTN 64141244. Journal of Clinical Oncology 2009;27(32):5390-6. 6678213
25. Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Annals of Oncology 2014;25(8):1622-8. 6678215
26. von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. Journal of Clinical Oncology 2012;30(9):907-13. 6678217
27. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, vant Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. Journal of Clinical Oncology 2003;21(18):3431-9.
28. Behringer K, Josting A, Schiller P, Eich HT, Bredenfeld H, Diehl V, et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Annals of Oncology 2004;15(7):1079-85.
29. Beyan C, Kaptan K, Ifran A, Öcal R, Ulutin C, Özturk B. The effect of radiologic imaging studies on the risk of secondary malignancy development in patients with Hodgkin lypmhoma. Clinical Lymphoma and Myeloma 2007;7(7):467-9.
30. Bhatia S, Robison L, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disesase. New England Journal of Medicine 1996;334(12):745-51.
31. Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT. Gastrointestinal cancer after treatment of Hodgkin's disease. International Journal of Radiation Oncology, Biology, Physics 1997;37(1):67-73.
32. Biti G, Cellai E, Magrini SM, Papi MG, Ponticelli P, Boddi V. Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. International Journal of Radiation Oncology, Biology, Physics 1994;29(1):25-31.
33. Boice JD, Jr. Carcinogenesis - a synopsis of human experience with external exposure in medicine. Health Physics 1988;55:621.
34. Boivin JF, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, et al. Incidence of second cancers in patients treated for Hodgkin's disease. Journal of the National Cancer Institute 1995;87(10):732-41.
35. Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998;83(9):812-23.
36. Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma. New England Journal of Medicine 2009;361(24):2390-1.
37. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society Series B 1972;34(2):187-220.
38. De Bruin ML, Sparidans J, van't Veer M, Noordijk E, Louwman MWJ, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller rafiation volumes. Journal of Clinical Oncology 2009;27(26):4239-46.
39. Diehl V, Harris N, Mauch P. Hodgkin's disease. In: De Vita VT editor(s). Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins, 2000. [ISBN 0-7817-2807-X]
40. Delwail V, Jais JP, Colonna P, Andrieu JM. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. British Journal of Haematology 2002;118(1):189-94.
41. Dietrich PY, Henry-Amar M, Cosset JM, Bodis S, Bosq J, Hayat M. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?. Blood 1994;84(4):1209-15.
42. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. Journal of Clinical Oncology 2002;20(16):3484-94.
43. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant Tamoxifen and of cytotoxic therapy on mortality in early breast cancer. New England Journal of Medicine 1988;319:1681-92.
44. Early Breast Cancer Triallists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992;339:1-15, 71-85.
45. Eichenauer D, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2014;123(11):1658-64.
46. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology 2009;27(27):4548-54.
47. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379(9828):1791-9.
48. Enrici RM, Anselmo AP, Iacari V, Osti MF, Santoro M, Tombolini V, et al. The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment. Haematologica 1998;83(7):636-44.
49. Foss-Abrahamsen J, Andersen A, Hannisdal E, Nome O, Foss-Abrahamsen A, Kvaloey S, et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time and age. Journal of Clinical Oncology 1993;11(2):255-61.
50. Foss-Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss-Abrahamsen J, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Annals of Oncology 2002;13(11):1786-91.
51. Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003187.pub2]
52. Franklin J, Pluetschow A, Paus M, Specht L, Amselmo A-P, Aviles A, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Annals of Oncology 2006;17(12):1749-60.
53. Franklin J, Hozo I, Pluetschow A, Djulbegovic B. Competing risks with time-to-event outcomes in an individual patient data meta-analysis. Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (gmds). 51. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie. Düsseldorf, Köln: German Medical Science, 2006; Vol. Doc 06gmds281.
54. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
55. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. Journal of the National Cancer Institute 1993;85(1):25-31.
56. Henry-Amar M. Second cancer after the treatment of Hodgkin's disease: a report from the International Database on Hodgkin's disease. Annals of Oncology 1992;3 Suppl 4:117-28.
57. Henry-Amar M, Dietrich PY. Acute leukemia after the treatment of Hodgkin's disease. Hematology/Oncology Clinics of North America 1993;7(2):369-87.
58. Henry-Amar M, Joly F. Late complications after Hodgkin's disease. Annals of Oncology 1996;7 Suppl 4:115-26.
59. Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2010;95(3):494-500.
60. Higgins JPT, Thompson SG. Quantifying heterogeneity in meta-analysis. Statistics in Medicine 2002;21:1539-58.
61. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). The Cochrane Collaboration (available from www.cochrane-handbook.org), 2011.
62. Hodgson DC, Gilbert ET, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. Journal of Clinical Oncology 2007;25(12):1489-97.
63. Iacobelli S. EBMT statistical guidelines. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 2013;48:S1-S37.
64. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 2003;21(18):3440-6.
65. Kaldor JM, Day NE, Clarke EA, van Leeuwen FE, Henry-Amar M, Fiorentino MV, et al. Leukemia following Hodgkin's disease. New England Journal of Medicine 1990;322:7-13.
66. Kaldor JM, Day NE, Bell J, Clarke EA, Langmark F, Karjalainen S, et al. Lung cancer following Hodgkin's disease: a case-control study. International Journal of Cancer 1992;52:677-81.
67. Koontz MZ, Horning S, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. Journal of Clinical Oncology 2013;31(5):592-8.
68. Koshy M, Rich SE, Mahmood U, Kwok Y. Declining use of radiotherapy in stage I and II hodgkin's disease and its effect on survival and secondary malignancies. International Journal of Radiation Oncology Biology Physics 2012;82(2):619-25.
69. Leone G1, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92(10):1389-98.
70. Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. Journal of Clinical Oncology 1998;16(3):818-29.
71. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996;87(9):3625-32.
72. Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM. Hodgkin's Disease. Philadelphia: Lippincott Williams and Wilkins, 1999.
73. Meattini I, Livi L, Saieva C, Marrazzo L, Rampini A, Iermano C, et al. Breast cancer following Hodgkin's disease: the experience of the University of Florence. Breast Journal 2010;16(3):290-6.
74. Meyer RM, Gospodarowicz MK, Connors, JM, Pearcey RG, Wells WA, Winter JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. New England Journal of Medicine 2012;366(5):399-408.
75. Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of Internal Medicine 2009;151(4):264-9.
76. Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, el al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4baseline): final results in stage III-IV low-risk Hodgkinlymphoma (IPS 0-2) of the LYSA H34 randomized trial. Annals of Oncology 2014;25(8):1622-8.
77. Mueller NE, Grufferman S. The epidemiology of Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM editor(s). Hodgkin's Disease. Philadelphia: Lippincott Williams and Wilkins, 1999:61-77.
78. Ng AK, Bernardo MVP, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100(6):1989-96.
79. Ng AK, Mauch PM. Late complications of therapy of Hodgkin's disease: Prevention and management. Current Hematology Reports 2004;3(1):27-33.
80. Pedersen-Bjergaard J, Specht L, Larsen SO, Ersboell J, Struck J, Hansen MM, et al. Risk of therapy-related leukemia and preleukemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987;2(8550):83-8.
81. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?. Statistics in Medicine 1993;12:737-51.
82. Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. Journal of Clinical Oncology 2014;32(12):1188-94.
83. The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.2. Copenhagen: The Cochrane Collaboration, 2012.
84. Rodriguez MA, Fuller LM, Zimmerman SO, Allen PK, Brown BW, Munsell MF, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Annals of Oncology 1993;4(2):125-31.
85. Rueffer U, Josting A, Franklin J, May M, Sieber M, Breuer K, et al. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin'sLymphoma Study Group: incidence, treatment, and prognosis. Journal of Clinical Oncology 2001;19(7):2026-32.
86. Sasse S, Klimm B, Gorgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Annals of Oncology 2012;23(11):2953-9.
87. Scholz M, Engert A, Franklin J, Josting A, Diehl V, Hasenclever D, et al. Impact of first- and second.line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL - experience of the German Hodgkin's Lymphoma Study Group analysed by a parametric model of carcinogenesis. Annals of Oncology 2011;22(3):681-8.
88. Shore T, Nelson N, Weinerman B. A Meta-analysis of stages I and II Hodgkin's disease. Cancer 1990;65:1155-60.
89. Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncology 2013;14(10):943-52.
90. Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3, 888 patients. Journal of Clinical Oncology 1998;16(3):830-43.
91. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992;304:1137-43.
92. Swerdlow AJ, Barber JA, Vaughan Hudson G, Cunningham D, Gupta RK, Hancock BW, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. Journal of Clinical Oncology 2000;18:498-509.
93. Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. Journal of Clinical Oncology 2001;19(6):1610-8.
94. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. Journal of Clinical Oncology 2011;29(31):4096-104.
95. Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a national cohort study. Journal of Clinical Oncology 2012;30(22):2745-52.
96. Tai BC, Machin D, White I, Gebski V. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Statistics in Medicine 2001;20:661-84.
97. Travis LB, Gospodarovicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. Journal of the National Cancer Institute 2002;94:182-92.
98. Travis LB, Hill DA, Dores GM, Gospodarovicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin's disease. JAMA 2003;290(4):465-75.
99. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. New England Journal of Medicine 1988;318:76-81.
100. Tucker MA. Solid second cancers following Hodgkin's disease. Hematology/Oncology Clinics of North America 1993;7(2):389-400.
101. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EHM, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. Journal of Clinical Oncology 1994;12:312-25.
102. van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EHM. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkalating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. Journal of Clinical Oncology 1994;12(5):1063-73.
103. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. Journal of the National Cancer Institute 1995;87(20):1530-7.
104. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, et al. Roles of radiotherapy dose, chemotherapy, and hormonal status in breast cancer following Hodgkin's disease. Journal of the National Cancer Institute 2003;95(13):971-80.
105. von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. Journal of Clinical Oncology 2012;30(9):907-13.
106. Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherpay for children with Hodgkin's lymphoma - a report from the Children's Oncology Group. Journal of Clinical Oncology 2012;30(26):3174-80.
107. Xavier AC, Armeson KE, Hill EG, Costa LJ. Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors. Cancer 2013;119(18):3385-92.
108. Franklin J, Eichenauer D, Monsef I, Engert A. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD008814]